Projected budget impact of pharmacotherapy scenarios for obesity and related conditions in Peru: A national survey analysis of 76,819 participants
Abstract
Background: The increasing prevalence of obesity is generating demand for chronic pharmacologic treatment, but Latin American evidence on population-level budget implications remains limited.
Methods: This was an observational, cross-sectional descriptive study using ENDES (Encuesta Demográfica y de Salud Familiar or Demographic and Family Health Survey) 2022-2024 data, with a deterministic scenario-based budget impact analysis component. Survey-observable candidate populations and gross medication-acquisition requirements were estimated under the complex survey design. Liraglutide, extended-release naltrexone/bupropion, and extended-release phentermine/topiramate were modeled, while semaglutide 2.4 mg served as a supplementary non-governmental retail scenario.
Results: The pooled file included 76,819 records. An estimated 7.54 million adults had Body Mass Index-defined obesity, 9.04 million met the broad criterion, and 3.67 million met pragmatic priority. At 100% coverage, broad-criterion annual budgets were S/142.95 billion for liraglutide, S/23.65 billion for the IETSI (Institute for Health Technology Assessment and Research)-reported naltrexone/bupropion scenario, and S/26.83 billion for phentermine/topiramate; corresponding pragmatic-priority budgets were S/57.95 billion, S/9.59 billion, and S/10.88 billion. Semaglutide 2.4 mg cost S/16,804.86 per patient in the first year and S/18,135.52 in a maintenance year.
Conclusion: In Peru, a substantial proportion of adults…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 54 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.